In collaboration with Duke Biomedical Engineering, we are testing the use of our antibodies in a novel diagnostic assay platform to develop point-of-care assays for the diagnosis of infections by agents such as Zika virus, Dengue virus, Salmonella typhi, and Aspergillus fumigatus.
Efforts are ongoing to develop point-of-care assays.
To obtain results within minutes and possibly to develop point-of-care (POC) techniques, some authors have proposed measurement of dabigatran and rivaroxaban in urine samples [ 79, 80].
WCL is listed as a co-inventor on a patent applied for by the University Health Network (Toronto, ON, Canada) to develop point-of-care tests for endothelial activation biomarkers in infectious diseases.
Finally, ABPP methodology is a useful tool that could be broadly applied to renal pathophysiological states to identify differentially activated enzymes; develop point-of-care monitoring assays; and potentially identify new therapeutic targets, such as specific enzyme inhibitors.
Previous attempts to develop point-of-use treatment systems capable of removing trace organic contaminants prior to nonpotable reuse have employed electrochemical processes, but these systems suffer from limitations including the production of toxic byproducts, an inability to remove recalcitrant compounds and high cost of treatment.
Chemiluminescence, i.e. the emission of light from a chemical reaction, offers interesting opportunities for developing point-of-care biosensors.
Whitesides, who holds at least 130 patents, has many years' experience developing point-of-care medical diagnostics, including a blood test for sickle-cell disease.
We sought to assess a newly developed point-of-care (POC) assay compared with presence of TF for guiding the use of antibiotics for trachoma control.
